LGVN Stock Overview
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$3.70|
|52 Week High||US$45.00|
|52 Week Low||US$2.84|
|1 Month Change||-22.68%|
|3 Month Change||-37.71%|
|1 Year Change||1.37%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-50.07%|
Recent News & Updates
Longeveron spikes after FDA’s Fast Track Designation for lead candidate
The shares of clinical-stage biotech Longeveron Inc. (NASDAQ:LGVN) jumped in the pre-market trading Wednesday after the company announced that the FDA issued Fast Track Designation for its lead asset Lomecel-B as a treatment for Hypoplastic Left Heart Syndrome (HLHS). A rare congenital cardiac defect impacting heart’s ability to pump blood, HLHS affects an estimated ~1,000 babies per year in the U.S. The FDA offers the Fast Track designation to accelerate the development and review of drugs targeted at serious conditions with unmet medical needs. It allows developers to communicate frequently with the regulator on plans for clinical studies. If certain criteria are met, such programs will also be able to win the Accelerated Approval and Priority Review, enabling them to reach patients sooner. A cell-based therapeutic candidate, Lomecel-B, is currently undergoing a Phase 2a randomized clinical trial involving 38 patients. In December, LGVN shares surged after the company announced FDA’s orphan drug designation for Lomecel-B in HLHS.
Is Longeveron (NASDAQ:LGVN) In A Good Position To Invest In Growth?
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
|LGVN||US Biotechs||US Market|
Return vs Industry: LGVN exceeded the US Biotechs industry which returned -25.8% over the past year.
Return vs Market: LGVN exceeded the US Market which returned -21.5% over the past year.
|LGVN Average Weekly Movement||11.1%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||15.6%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: LGVN is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: LGVN's weekly volatility has decreased from 45% to 11% over the past year, but is still higher than 75% of US stocks.
About the Company
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company’s lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer’s disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome.
Longeveron Fundamentals Summary
|LGVN fundamental statistics|
Is LGVN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|LGVN income statement (TTM)|
|Cost of Revenue||US$584.00k|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.86|
|Net Profit Margin||-1,414.10%|
How did LGVN perform over the long term?See historical performance and comparison
Is LGVN undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 1/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for LGVN?
Other financial metrics that can be useful for relative valuation.
|What is LGVN's n/a Ratio?|
Price to Book Ratio vs Peers
How does LGVN's PB Ratio compare to its peers?
|LGVN PB Ratio vs Peers|
|Company||PB||Estimated Growth||Market Cap|
FBIO Fortress Biotech
AXLA Axcella Health
AURX Nuo Therapeutics
ELYM Eliem Therapeutics
Price-To-Book vs Peers: LGVN is good value based on its Price-To-Book Ratio (2.6x) compared to the peer average (10.9x).
Price to Earnings Ratio vs Industry
How does LGVN's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Book vs Industry: LGVN is expensive based on its Price-To-Book Ratio (2.6x) compared to the US Biotechs industry average (1.6x)
Price to Book Ratio vs Fair Ratio
What is LGVN's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PB Ratio||2.6x|
|Fair PB Ratio||n/a|
Price-To-Book vs Fair Ratio: Insufficient data to calculate LGVN's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of LGVN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate LGVN's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate LGVN's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
How is Longeveron forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: LGVN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: LGVN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: LGVN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: LGVN's revenue is expected to decline over the next 3 years (-45.5% per year).
High Growth Revenue: LGVN's revenue is forecast to decline over the next 3 years (-45.5% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if LGVN's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Longeveron performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: LGVN is currently unprofitable.
Growing Profit Margin: LGVN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: LGVN is unprofitable, and losses have increased over the past 5 years at a rate of 45.8% per year.
Accelerating Growth: Unable to compare LGVN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LGVN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).
Return on Equity
High ROE: LGVN has a negative Return on Equity (-61.46%), as it is currently unprofitable.
Discover strong past performing companies
How is Longeveron's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: LGVN's short term assets ($28.2M) exceed its short term liabilities ($3.6M).
Long Term Liabilities: LGVN's short term assets ($28.2M) exceed its long term liabilities ($2.3M).
Debt to Equity History and Analysis
Debt Level: LGVN is debt free.
Reducing Debt: LGVN had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: LGVN has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: LGVN has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of 40.3% each year.
Discover healthy companies
What is Longeveron current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
|Longeveron Dividend Yield vs Market|
|Market Bottom 25% (US)||1.7%|
|Market Top 25% (US)||4.7%|
|Industry Average (Biotechs)||2.8%|
|Analyst forecast in 3 Years (Longeveron)||n/a|
Notable Dividend: Unable to evaluate LGVN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate LGVN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if LGVN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if LGVN's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as LGVN has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Chris Min (55 yo)
Dr. Kwan-Hong Min, also known as Christopher & Chris, MD, PhD, serves as Chief Medical Officer of Longeveron Inc. from April 04, 2022 and also serves as its Interim Chief Executive Officer since June 01, 2...
Experienced Management: LGVN's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Experienced Board: LGVN's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
|03 Jun 22||SellUS$305,248||James Clavijo||Individual||36,955||US$8.26|
|24 May 22||SellUS$152,635||Rock Soffer||Individual||19,500||US$8.06|
|13 Oct 21||BuyUS$72,855||Rock Soffer||Individual||19,900||US$3.76|
|13 Oct 21||BuyUS$3,810||Geoff Green||Individual||1,000||US$3.81|
|12 Oct 21||BuyUS$9,225||Joshua Hare||Individual||2,500||US$3.69|
|08 Oct 21||BuyUS$16,930||Joshua Hare||Individual||5,000||US$3.39|
|07 Oct 21||BuyUS$5,845||Paul Lehr||Individual||1,750||US$3.34|
|07 Oct 21||BuyUS$16,700||James Clavijo||Individual||5,000||US$3.34|
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9.8%.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Longeveron Inc.'s employee growth, exchange listings and data sources
- Name: Longeveron Inc.
- Ticker: LGVN
- Exchange: NasdaqCM
- Founded: 2014
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$77.652m
- Shares outstanding: 20.99m
- Website: https://www.longeveron.com
Number of Employees
- Longeveron Inc.
- 1951 NW 7th Avenue
- Suite 520
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|LGVN||NasdaqCM (Nasdaq Capital Market)||Yes||Class A Common Stock||US||USD||Feb 2021|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/09/30 00:00|
|End of Day Share Price||2022/09/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.